Date Announced: 23 May 2019
Train of laser pulses stimulate lachrymal and Meibomian glands.
The LUMIBIRD Group (Paris:LBIRD), the European leader for laser technologies, has obtained through its subsidiary Quantel Medical the CE mark aproval for its new device for treating dry eye diseases: the LacrySTIM™ IPL. With a product range now covering diagnosis - with LacryDiag ™ - to treatment, LUMIBIRD provides healthcare professionals with a complete and innovative solution to address the pathology of dry eye.
Dry eye disease is a multifactorial disease of the tears and ocular surface that can result in ocular discomfort and visual impairment. It affects all populations across the world with a major increase in people over 50 years old.
LacrySTIM™ IPL is a treatment device featuring a unique wavelengths spectrum and train of pulses enabling the stimulation of the lachrymal and Meibomian glands and the reduction of inflammation. These mechanisms of action help the improvement of the tear film quality and the reduction the major symptoms associated with mild to moderate dry eye diseases.
“LacrySTIM™ IPL system brings an innovative therapeutic solution to ophthalmologists confronted to the daily challenge of dry eye treatment. It complements ideally with LacryDiag™, our dry eye diagnostic platform launched in 2018.” said Jean-Marc Gendre, CEO of Quantel Medical.
For Marc Le Flohic, Chairman and CEO of the LUMIBIRD Group, "The dynamism and expertise of our Quantel Medical team allow us to continue developing the business while controlling our structural costs. With a complete range from diagnosis to treatment of dry eye diseases, we are entering into a new high-potential market for which the needs are vast and solutions are still rare. We are thus strengthening our position in the field of ophthalmology while improving our business model."
E-mail: via web site
Web Site: www.lumibird.com